Paxlovid is “a prescription oral antiviral drug that reduces the risk of hospitalization”
People who took the coronavirus drug Paxlovid may experience a ‘rebound in Covid-19 symptoms’, according to a study published last month in the journal Clinical Infectious Diseaseswho claims that it is the result of insufficient intake of the drug.
The study was carried out by researchers at the University of California San Diego School of Medicine, where they described that symptoms of Covid-19 can return in patients after treatment ends.
Paxlovid is “a prescription oral antiviral drug that reduces the risk of hospitalization and death in patients with mild to moderate Covid-19 who are at risk of worsening disease”.
A clinical trial presented the drug’s ability to reduce the risk of hospitalization and death from Covid-19 by 89%.
The researchers determined that insufficient intake of Paxlovid was responsible for the relapses by examining a patient whose return of symptoms “was not due to the development of resistance to the drug.”
The research team concluded that Covid-19 was still susceptible to Paxlovid and had no relevant mutations that could reduce the drug’s effectiveness.
“Our main concern was that the coronavirus might develop resistance to Paxlovid, but it’s not,” said Aaron F. Carlin, one of the study’s authors and assistant professor at the University College of Medicine. UC San Diego.
In Israel, the peak of the 6th wave has been reached and the number of infections is starting to drop.
–
